In China, smeglutide has been approved to treat adult type 2 diabetes and reduce the risk of cardiovascular adverse events in type 2 diabetes patients with cardiovascular disease, but its weight loss indication has not yet been approved. In addition, there are many adverse reactions and contraindications when using smectide. Patients need to obtain the drug through regular hospital channels and use it under the guidance of a doctor. Whether in China or abroad, there are many precautions and conditions for the use of smectide, and it is not a "weight loss tool" that everyone can use. Summer has arrived, and weight loss has been talked about by many beauty enthusiasts. Many people also share various weight loss methods such as exercising, dieting, and eating fat reducing meals on social media accounts. Recently, some netizens shared a "weight loss tool" they purchased online that does not require dieting or exercise. It is said that "one shot has lost 16 pounds". It is understood that this so-called "weight loss artifact", called "smeglutide injection", is a prescription drug for the treatment of type 2 diabetes. Can Smegglutide be used for weight loss? Can people with weight loss needs purchase related products online on their own? With these questions in mind, a reporter from Science and Technology Daily interviewed relevant experts. Smegglutide is a novel long-acting glucagon like peptide-1 (GLP-1) analogue that can effectively control glucose and improve multiple cardiovascular metabolic indicators. It not only enhances insulin secretion but also effectively inhibits glucagon secretion, thereby lowering blood sugar levels. In addition to effective sugar control, smeagllutide can also improve multiple cardiovascular metabolic indicators and better comprehensively control various cardiovascular risk factors, including blood pressure, blood lipids, and body weight. In fact, Smeglutide was first known as a "once a week" hypoglycemic drug. As early as December 2017, Smeaglutide was approved by the US Food and Drug Administration (FDA) to control blood sugar in adult patients with type 2 diabetes; In January 2020, FDA again approved smeglutide for adult type 2 diabetes patients with cardiovascular disease to reduce the risk of related diseases; In June 2021, the drug was approved for long-term weight management in the United States. FDA approved Smeaglutide to be applicable to patients with body mass index (BMI) greater than or equal to 30 in the adult population, and adult overweight people (BMI greater than or equal to 27) with at least one weight related disease (such as hypertension, type 2 diabetes or high cholesterol). Smegglutide does have a certain effect on weight loss. On the one hand, it inhibits the feeding center of the hypothalamus, making people feel hungry and suppressing appetite. On the other hand, it can act on the gastrointestinal tract, delaying gastric emptying, and increasing satiety. "Fang Hongjuan, deputy chief physician of the Endocrine Department at Beijing Tiantan Hospital, told reporters that Smegglutide actually suppresses patients' appetite and makes them feel full after eating a little, Eating too much can cause discomfort, thereby reducing calorie intake and achieving weight loss. In China, the weight loss indication of smeglutide has not yet been approved. In April 2021, smeglutide was approved in mainland China to treat adult type 2 diabetes and reduce the risk of cardiovascular adverse events in type 2 diabetes patients with cardiovascular disease; In December of the same year, the drug was included in the national medical insurance